Related Experiment Videos
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure]
1Universitair Medisch Centrum St Radboud, afd. Algemeen Interne Geneeskunde en Vasculaire Geneeskunde, 463, Postbus 9101, 6500 HB Nijmegen. a.stalenhoef@aig.umcn.nl
Insights
Lowering blood pressure significantly reduces stroke risk. High-dose statins also prevent strokes in high-risk patients, but require careful consideration due to costs and side effects.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Context:
- Blood pressure is the primary stroke risk factor.
- Statins have emerged as beneficial for stroke prevention.
- Secondary prevention guidelines apply to patients with a history of stroke or TIA.
Purpose:
- To summarize the impact of blood pressure management and statin therapy on stroke prevention.
- To highlight findings from the SPARCL trial regarding high-dose statin use.
- To discuss the benefits and risks of statin therapy in secondary stroke prevention.
Summary:
- Reducing systolic or diastolic blood pressure lowers stroke incidence by 30-40% in the general population.
- The SPARCL trial demonstrated that high-dose statins reduce fatal and non-fatal stroke risk in patients with prior ischemic stroke or TIA.
- A 1.4 mmol/l reduction in LDL-cholesterol correlated with a 2.2% absolute 5-year risk reduction in stroke.
Impact:
- Effective blood pressure control is crucial for primary stroke prevention.
- High-dose statin therapy offers significant secondary prevention benefits for select high-risk stroke patients.
- Careful patient selection is necessary for high-dose statin therapy due to cost, adverse effects, and potential increased risk of hemorrhagic stroke.
Abstract:
The most important risk factor for stroke is blood pressure: lowering the diastolic pressure by 5-6 mmHg or the systolic pressure by 10 mmHg will reduce the number of strokes in the general population (primary prevention) by 30-40% over 4-5 years. This effect is enhanced by the concurrent use of diuretics. The association between stroke and serum cholesterol was unclear until trials on preventing cardiovascular disease showed the introduction of statins to be clearly beneficial on strokes. In the recent 'Stroke prevention by aggressive reduction in cholesterol levels' (SPARCL) trial, high-dose statin therapy was shown to reduce the risk of fatal and non-fatal stroke in patients with a history of ischaemic stroke or transient ischaemic attack (TIA), but without manifest coronary disease (secondary prevention). A difference in LDL-cholesterol of 1.4 mmol/l was associated with a significant absolute 5-year risk reduction of fatal and non-fatal stroke of 2.2%, whereas the risk of major cardiovascular events was reduced by 3.5%. It is already known that stroke or TIA should be regarded as a 'coronary heart disease risk equivalent' for which secondary prevention guidelines apply. However, high-dose statin therapy should be given only after careful selection of the stroke patient at very high risk because of its high cost, adverse effects and a possible increase in haemorrhagic stroke.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis IV: Nursing Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Peripheral Artery Disease III: Interprofessional Care
Hypertension IV: Drug Therapy and Lifestyle Modifications